Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Phase 2 subjects on 150mg/day averaged 13.8% weight loss with no muscle loss reported
Your plan is guided by your symptoms, your biology and your priorities
Injectable routes carry a particular concern for immunogenicity from peptide aggregation and impurities, and FDA noted the available certificates of analysis for AOD-9604 bulk drug substances did not consistently control for impurities, aggregates, or microbial limits
The therapys success is checked by looking at clinical markers
Realistic expectations include gradual improvements in body composition over an 8-12 week period
US$ 29.35
US$ 23.71
US$ 24.63
US$ 26.03
